| Literature DB >> 23717137 |
Abstract
Thousands of literatures have described the diverse role of ginseng in physiological processes such as cancer, neurodegenerative disorders, insulin resistance, and hypertension. In particular, ginseng has been extensively reported to maintain homeostasis of the immune system and to enhance resistance to illness or microbial attacks through the regulation of immune system. Immune system comprises of different types of cells fulfilling their own specialized functions, and each type of the immune cells is differentially influenced and may be simultaneously controlled by ginseng treatment. This review summarizes the current knowledge on the effects of ginseng on immune system. We discuss how ginseng regulates each type of immune cells including macrophages, natural killer cells, dendritic cells, T cells, and B cells. We also describe how ginseng exhibits beneficial effects on controlling inflammatory diseases and microbial infections.Entities:
Keywords: Acquired immunity; Cytokine; Immunomodulation; Innate immunity; Panax ginseng
Year: 2012 PMID: 23717137 PMCID: PMC3659612 DOI: 10.5142/jgr.2012.36.4.354
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Fig. 1.Structures of saponins from Panax ginseng. (A) Protopanaxadiol- and protopanaxatriol-type saponins, (B) ginsenoside Ro, and (C) compound K. Glc, β-D-glucose; Ara(p), arabinose (pyranose form); Ara(f), arabinose (furanose form); Rha, α-L-rhamnose.
Summary of the ginseng effects on immune system
| Effects | References | |
|---|---|---|
|
| ||
| Innate immunity | ||
| Macrophages | Enhance phagocytosis | |
| Stimulate the generation of nitric oxide | ||
| Induce inflammatory reactions by IL-1β and TNF-α | ||
| Stimulate NK cells and T cells by IL-12 | ||
| DCs | Increase DC maturation markers (MHC class II, CD80, CD83, CD86) | |
| Increase the production of IL-1 and TNF-α | ||
| Reduce DC maturation markers (CD40, CD86, CD1a, HLA-DR) | ||
| Diminish the secretion of TNF-α, IL-12 and IL-12 p40 | ||
| NK cells | Improve natural killing activity | |
| Acquired immunity | ||
| Humoral immunity | Induce responses and production of IgA, IgM, IgG and IgG subunits | |
| Inhibit the OVA-sensitized decrease in IgA level in the small intestine | ||
| Cell-mediated immunity | Enhance antibody-dependent cellular cytotoxicity | |
| Stimulate T cell proliferation | ||
| Promote the generation of immunosuppressive regulatory T cells (Tregs) | ||
| Cytokine release | ||
| Of innate immunity | Produce TNF-α, IL-1β, IL-6, and IFN-γ by macrophages | |
| Increase IL-2, IFN-γ, IL-1α, and GM-CSF production | ||
| Decrease TNF-α, IL-1β, IL-6, IFN-γ, IL-12, and IL-18 by TLR reduction | ||
| Reduce nitric oxide synthesis and production of TNF-α and IL-1β | ||
| Inhibit secretion of IL-1β, IL-17 and IFN-γ | ||
| Of acquired immunity | Enhance production of IFN-γ and IL-2 | |
| Increase generation of IL-1, IL-6, IFN-γ, and IL-12 | ||
| Increase Th2 cytokine (e.g., IL-4) and repress Th1 cytokine (e.g., IFN-γ) | ||
| Stimulate Th1 and Th2 cytokine equally (IFN-γ, IL-2, IL-4, IL-10, and TNF-α) | ||
| Inflammatory disease regulation | ||
| Mitigate asthma symptoms suppressing airway hyperresponsiveness | ||
| Protect host from bacterial septic responses | ||
| Modulate CNS inflammation and improve cerebral ischemia | ||
| Ameliorate arthritis by reducing inflammatory cell infiltration, cytokine production, and cartilage destruction | ||
| Alleviate atopic dermatitis by decreasing inflammatory cytokines | ||
| Anti-microbial activity | ||
| Bacteria | Interrupt microbial adhesion to host cells | |
| Kill Gram positive and Gram nagative bacteria directly | ||
| Inhibit survival or pathogenic mechanism of specific pathogen | ||
| Enhance bacterial clearance and decrease pathology | ||
| Interrupt quorum sensing system | ||
| Influenza virus | Increase antibody production and response with influenza virus A/PR8 infection | |
| Reduced ROS stress, IP-10, influenza-induced DNA damage and apoptosis in H9N2 infection | ||
| Inhibit proliferation of influenza virus A (H1N1) | ||
| HIV-1 | Increase the frequency of gross deletion in the | |
| Increases the frequency of gross deletion in HIV-1 5’ LTR/ gag regions | ||
| Others | Inhibit viral growth of rotavirus, MNV and FCV | |
| Adjuvant | ||
| Improve antibody production and responsiveness (IgM, IgG, and IgG subunits) | ||
| Activate mixed Th1 and Th2 immune responses | ||
NK, natural killer; DC, dendritic cells; MHC, major histocompatibility complex; OVA, ovalbumin; GM-CSF, granulocyte-macrophage colony-stimulating factor; CNS, central nervous system; ROS, reactive oxygen species; HIV-1, human immunodeficiency virus type 1; MNV, murine norovirus; FCV, feline calicivirus.